161 related articles for article (PubMed ID: 22427410)
21. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
22. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
23. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
Kiltz U; Heldmann F; Baraliakos X; Braun J
Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
[TBL] [Abstract][Full Text] [Related]
24. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.
Stone MA; Inman RD; Wright JG; Maetzel A
Arthritis Rheum; 2004 Jun; 51(3):316-20. PubMed ID: 15188313
[TBL] [Abstract][Full Text] [Related]
25. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
26. What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.
van Weely SF; van Denderen JC; Steultjens MP; Nurmohamed MT; Dijkmans BA; Dekker J; van der Horst-Bruinsma IE
Rheumatology (Oxford); 2013 Oct; 52(10):1884-9. PubMed ID: 23864170
[TBL] [Abstract][Full Text] [Related]
27. [Meta-analysis of efficacy of anti-TNF alpha therapy in ankylosing spondylitis patients].
Montilla Salas J; Muñoz Gomáriz E; Collantes E
Reumatol Clin; 2007 Sep; 3(5):204-12. PubMed ID: 21794432
[TBL] [Abstract][Full Text] [Related]
28. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
[TBL] [Abstract][Full Text] [Related]
30. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
31. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
32. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide.
van den Berg R; Stanislawska-Biernat E; van der Heijde DM
Rheumatology (Oxford); 2011 Dec; 50(12):2270-7. PubMed ID: 22019804
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
35. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.
Brandt J; Listing J; Sieper J; Rudwaleit M; van der Heijde D; Braun J
Ann Rheum Dis; 2004 Nov; 63(11):1438-44. PubMed ID: 15044211
[TBL] [Abstract][Full Text] [Related]
36. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
Elewaut D; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
[TBL] [Abstract][Full Text] [Related]
37. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Haibel H; Sieper J
Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
[TBL] [Abstract][Full Text] [Related]
38. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients.
Gérard S; le Goff B; Maugars Y; Berthelot JM
Joint Bone Spine; 2008 Dec; 75(6):680-7. PubMed ID: 18848489
[TBL] [Abstract][Full Text] [Related]
39. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
40. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
